Pathophysiology of diabetic erectile dysfunction: Potential contribution of vasa nervorum and advanced glycation endproducts

International Journal of Impotence Research

Volumn 25, Issue 1, 2013, Pages 1-6

  Cellek, S ^a   Cameron, N E ^b   Cotter, M A ^b   Muneer, A ^c  

^a CRANFIELD UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Advanced glycation endproducts; diabetes mellitus; erectile dysfunction; hypoxia; microvessel; nitric oxide; vasa nervorum

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTIC PROTEINASE INHIBITOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

BASAL GANGLION; BLOOD FLOW; BLOOD VESSEL; CORPUS CAVERNOSUM; DIABETES MELLITUS; DISEASE COURSE; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOXIA; NERVE FIBER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

DIABETIC NEUROPATHIES; ERECTILE DYSFUNCTION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; VASA NERVORUM;

EID: 84872502252     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2012.30     Document Type: Review

References (102)

1. Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, Paick JS et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 2010; 7: 445-475.
2. Moncada S, Higgs A, Furchgott R. International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacol Rev 1997; 49: 137-142.
3. Cellek S. Let's make NO mistake! Int J Impot Res 2005; 17: 388-389.
4. Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2002; 99: 4061-4066.
5. Cameron NE, Cotter MA. Erectile dysfunction and diabetes mellitus: mechanistic considerations from studies in experimental models. Curr Diab Rev 2007; 3: 149-158.
6. Chitaley K, Kupelian V, Subak L, Wessells H. Diabetes, obesity and erectile dysfunction: field overview and research priorities. J Urol 2009; 182: S45-S50.
7. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001; 68: 928-944.
8. Jackson G. Erectile dysfunction: a marker of silent coronary artery disease. Eur Heart J 2006; 27: 2613-2614.
9. Cellek S. Nitrergic-noradrenergic interaction in penile erection: a new insight into erectile dysfunction. Drugs Today (Barc) 2000; 36: 135-146.
10. Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectilefunction. Pharmacol Ther 2005; 106: 233-266.
11. Ritchie R, Sullivan M. Endothelins & erectile dysfunction. Pharmacol Res 2011; 63: 496-501.
12. Zhang XH, Melman A, Disanto ME. Update on corpus cavernosum smooth muscle contractile pathways in erectile function: a role for testosterone? J Sex Med 2011; 8: 1865-1879.
13. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in strep-tozotocin-induced diabetic rats. Diabetes 2003; 52: 2353-2362.
14. Cellek S, Anderson PN, Foxwell NA. Nitrergic neurodegeneration in cerebral arteries of streptozotocin-induced diabetic rats: a new insight into diabetic stroke. Diabetes 2005; 54: 212-219.
15. MacKenzie A, Cooper EJ, Dowell FJ. Differential effects of glucose on agonist-induced relaxations in human mesenteric and subcutaneous arteries. Br J Pharmacol 2008; 153: 480-487.
16. Houben AJ, Schaper NC, de Haan CH, Huvers FC, Slaaf DW, de Leeuw PW et al. Local 24-h hyperglycemia does not affect endothelium-dependent or -inde-pendent vasoreactivity in humans. Am J Physiol 1996; 270: H2014-H2020.
17. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246-2252.
18. Akbari CM, Saouaf R, Barnhill DF, Newman PA, LoGerfo FW, Veves A. Endo-thelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. J Vasc Surg 1998; 28: 687-694.
19. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-1701.
20. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146-154.
21. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000; 36: 2185-2191.
22. Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990; 85: 929-932.
23. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C J Clin Invest 1991; 87: 1643-1648.
24. Way KJ, Reid JJ. Effect of diabetes and elevated glucose on nitric oxide-mediated neurotransmission in rat anococcygeus muscle. Br J Pharmacol 1995; 115: 409-414.
25. Utkan T, Yildiz F, Utkan NZ, Gacar N, Gocmez SS, Ulak G et al. Effects of diabetes and elevated glucose on nitrergic relaxations in the isolated duodenum of the rat. Acta Diabetol 2009; 46: 295-301.
26. Cellek S. Point of NO return for nitrergic nerves in diabetes: a new insight into diabetic complications. Curr Pharm Des 2004; 10: 3683-3695.
27. Ari G, Vardi Y, Finberg JP. Nitric oxide and penile erection in streptozotocin-diabetic rats. Clin Sci (Lond) 1999; 96: 365-371.
28. Vernet D, Cai L, Garban H, Babbitt ML, Murray FT, Rajfer J et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995; 136: 5709-5717.
29. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental dia-betes in rats: relation to conduction deficits. Am J Physiol 1991; 261: E1-E8.
30. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973-1988.
31. Coppey LJ, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles thatoverliethe sciatic nerve. IntJExp Diab Res 2000; 1: 131-143.
32. Cameron NE, Cotter MA. Diabetes causes an early reduction in autonomic ganglion blood flow in rats. J Diab Complications 2001; 15: 198-202.
33. Cameron NE, Cotter MA. Impaired corpus cavernosum responses to cavernous nerve stimulation in diabetic rats: effects of treatment with erythropoietin-delta. Autonom Neurosci 2009; 149: 24-25.
34. Dail WG. The pelvic plexus: innervation of pelvic and extrapelvic visceral tissues. Microsc Res Tech 1996; 35: 95-106.
35. Zochodne DW. Nerve and ganglion blood flow in diabetes: an appraisal. Int Rev Neurobiol 2002; 50: 161-202.
36. Appenzeller O, Dhital KK, Cowen T, Burnstock G. The nerves to blood vessels supplying blood to nerves: the innervation of vasa nervorum. Brain Res 1984; 304: 383-386.
37. Cellek S, Smith S, Cameron NE, Cotter MA, Muneer A. Nitrergic innervation of vasa nervorum supplying the major pelvic ganglion. J Sex Med 2011; 8: 407.
38. Muneer A, Cellek S, Dogan A, Kell PD, Ralph DJ, Minhas S. Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model. Int J Impot Res 2005; 17: 10-18.
39. Prabhakar NR, Pieramici SF, Premkumar DR, Kumar GK, Kalaria RN. Activation of nitric oxide synthase gene expression by hypoxia in central and peripheral neurons. Brain Res Mol Brain Res 1996; 43: 341-346.
40. Prabhakar NR, Rao S, Premkumar D, Pieramici SF, Kumar GK, Kalaria RK. Reg-ulation of neuronal nitric oxide synthase gene expression by hypoxia. Role of nitric oxide in respiratory adaptation to low pO2. Adv Exp Med Biol 1996; 410: 345-348.
41. Phelan MW, Faller DV. Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J Cell Physiol 1996; 167: 469-476.
42. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999; 26: 74-84.
43. Wei IH, Huang CC, Chang HM, Tseng CY, Tu HC, Wen CY et al. Neuronal NADPH-d/NOS expression in the nodose ganglion of severe hypoxic rats with or without mild hypoxic preconditioning. J Chem Neuroanat 2005; 29: 149-156.
44. Serrano J, Encinas JM, Fernandez AP, Rodrigo J, Martinez A. Effects of acute hypobaric hypoxia on the nitric oxide system of the rat cerebral cortex: pro-tective role of nitric oxide inhibitors. Neuroscience 2006; 142: 799-808.
45. Yamamoto Y, Henrich M, Snipes RL, Kummer W. Altered production of nitric oxide and reactive oxygen species in rat nodose ganglion neurons during acute hypoxia. Brain Res 2003; 961: 1-9.
46. Mbaku EM, Zhang L, Pearce WJ, Duckles SP, Buchholz J. Chronic hypoxia alters the function of NOS nerves in cerebral arteries of near-term fetal and adult sheep. J Appl Physiol 2003; 94: 724-732.
47. Benesova P, Langmeier M, Betka J, Trojan S. Long-lasting changes in the density of nitrergic neurons following kainic acid administration and chronic hypoxia. Physiol Res 2005; 54: 565-571.
48. Hu J, Chin CM, Png JC, Ng YK, Ling EA. The effect of chronic bladder outlet obstruction on neuronal nitric oxide synthase expression in the intramural ganglia of the guinea pig bladder. J Urol 2004; 172: 1160-1165.
49. Prabhakar NR, Peng YJ, Jacono FJ, Kumar GK, Dick TE. Cardiovascular alterations by chronic intermittent hypoxia: importance of carotid body chemoreflexes. Clin Exp Pharmacol Physiol 2005; 32: 447-449.
50. Somjen GG, Aitken PG, Czeh G, Jing J, Young JN. Cellular physiology of hypoxia of the mammalian central nervous system. Res Publ Assoc Res Nerv Ment Dis 1993; 71: 51-65.
51. Leblond J, Krnjevic K. Hypoxic changes in hippocampal neurons. J Neurophysiol 1989; 62: 1-14.
52. Schneider U, Quasthoff S, Mitrovic N, Grafe P. Hyperglycaemic hypoxia alters after-potential and fast K+ conductance of rat axons by cytoplasmic acidifica-tion. J Physiol 1993; 465: 679-697.
53. Hendriksen PH, Oey PL, Wieneke GH, van Huffelen AC, Gispen WH. Hypoxic neuropathy versus diabetic neuropathy. An electrophysiological study in rats. J Neurol Sci 1992; 110: 99-106.
54. Tomlinson DR, Mayer JH. Defects of axonal transport in diabetes mellitus-a possible contribution to the aetiology of diabetic neuropathy.JAuton Pharmacol 1984; 4: 59-72.
55. Thomas PK, King RH, Feng SF. Muddle JR, Workman JM, Gamboa J, et al. Neuro-logical manifestations in chronic mountain sickness: the burning feet-burning hands syndrome. J Neurol Neurosurg Psychiatry 2000; 69: 447-452.
56. Greene DA, De Jesus PVJ, Winegrad AI. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 1975; 55: 1326-1336.
57. Biessels GJ, Stevens EJ, Mahmood SJ, Gispen WH,Tomlinson DR. Insulin partially reverses deficits in peripheral nerve blood flow and conduction in experimental diabetes. J Neurol Sci 1996; 140: 12-20.
58. Ziegler D, Cicmir I, Mayer P, Wiefels K, Gries FA. The natural course of peripheral and autonomic neural function during the first two years after diagnosis of type 1 diabetes. Klin Wochenschr 1988; 66: 1085-1092.
59. Ziegler D, Cicmir I, Mayer P, Wiefels K, Gries FA. Somatic and autonomic nerve function during the first year after diagnosis of type 1 (insulin-dependent) dia-betes. Diab Res 1988; 7: 123-127.
60. Lehtinen JM, Niskanen L, Hyvonen K, Siitonen O, Uusitupa M. Nerve function and its determinants in patients with newly-diagnosed type 2 (non-insulin-depen-dent) diabetes mellitus and in control subjects-a 5-year follow-up. Diabetologia 1993; 36: 68-72.
61. SoldersThalme G, Aguirre-Aquino B, Brandt M, Berg L, Persson U. A. Nerve conduction and autonomic nervefunction in diabetic children. A 10-year follow-up study. Acta Paediatr 1997; 86: 361-366.
62. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48: 643-648.
63. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
64. Duckworth WC, Abraira C, MoritzTE, Davis SN, Emanuele N, Goldman S et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diab Complications 2011; 25: 355-361.
65. Kent S. Is diabetes a form of accelerated aging? Geriatrics 1976; 31: 140, 145, 149-140, 145, 151.
66. Del TS, Basta G. An update on advanced glycation endproducts and atherosclerosis. Biofactors 2012.
67. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney IntSuppl 2000; 77: S26-S30.
68. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
69. Berner AK, Brouwers O, Pringle R, Klaassen I, Colhoun L, McVicar C et al. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012; 55: 845-854.
70. Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T et al. Over-expression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 2011;286: 1374-1380.
71. Brouwers O, Niessen PM, Haenen G, Miyata T, Brownlee M, Stehouwer CD et al. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 2010; 53: 989-1000.
72. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-1070.
73. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann NY Acad Sci 2011; 1243: 88-102.
74. Dhar A, Dhar I, Desai KM, Wu L Methylglyoxal scavengers attenuate endothelial dysfunction induced by methylglyoxal and high concentrations of glucose. Br J Pharmacol 2010; 161: 1843-1856.
75. Dhar I, Dhar A, Wu L, Desai K. D-arginine attenuates methylglyoxal- and high glucose-induced endothelial dysfunction and oxidative stress by an eNOS-independent mechanism. J Pharmacol Exp Ther 2012.
76. Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci (Lond) 2011; 120: 357-375.
77. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997; 50: 1016-1026.
78. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001; 87: 402-407.
79. Cellek S, Qu W, Schmidt AM, Moncada S. Synergistic action of advanced glyca-tion end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabeto-logia 2004; 47: 331-339.
80. Ramasamy R, Schmidt AM. Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep 2012; 9: 107-116.
81. Ma L, Carter RJ, Morton AJ, Nicholson LF. RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. Brain Res 2003; 966: 167-174.
82. Cameron NE, Cotter MA, Robertson S. Rapid reversal of a motor nerve con-duction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril. Acta Diabetol 1993; 30: 46-48.
83. Archibald V, Cotter MA, Keegan A, Cameron NE. Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 584-591.
84. Usta MF, Bivalacqua TJ, Yang DY, Ramanitharan A, Sell DR, Viswanathan A et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003; 170: 1437-1442.
85. Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006; 3: 242-250.
86. Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation. Gerontology 2012; 58: 227-237.
87. Hackett G. PDE5 inhibitors in diabetic peripheral neuropathy. Int J Clin Pract 2006; 60: 1123-1126.
88. Miclescu A, Gordh T. Nitric oxide and pain: 'Something old, something new'. Acta Anaesthesiol Scand 2009; 53: 1107-1120.
89. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994-1003.
90. Cameron N, Cotter M, Inkster M, Nangle M. Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diab Res Clin Pract 2003; 61(Suppl 1): S35-S39.
91. Ii M, Nishimura H, Kusano KF, Qin G, Yoon YS, Wecker A et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005; 112: 93-102.
92. Cameron NE, Cotter MA, Ferguson K, Robertson S, Radcliffe MA. Effects of chronic alpha-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols, Na (+) -K (+) -ATPase activity, and vascular supply in STZ-D rats. Diabetes 1991; 40: 1652-1658.
93. Cotter MA, Cameron NE. Correction of neurovascular deficits in diabetic rats by beta2-adrenoceptor agonist and alpha1-adrenoceptor antagonist treatment: interactions with the nitric oxide system. Eur J Pharmacol 1998; 343: 217-223.
94. Reja A, Tesfaye S, Harris ND, Ward JD, Is ACE. inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med 1995; 12: 307-309.
95. Malik RA. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors? Ann Med 2000; 32: 1-5.
96. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-1981.
97. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Yorek MA. Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring) 2008; 16: 82-89.
98. Maxfield EK, Love A, Cotter MA, Cameron NE. Nerve function and regeneration in diabetic rats: effects of ZD-7155, an AT1 receptor antagonist. Am J Physiol1995; 269: E530-E537.
99. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Dake B, Yorek MA. Role of the effect of inhibition of neutral endopeptidase on vascular and neural com-plications in streptozotocin-induced diabetic rats. Eur J Pharmacol 2011; 650: 556-562.
100. Ropper AH, Gorson KC, Gooch CL, Weinberg DH, Pieczek A, Ware JH et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009; 65: 386-393.
101. Schratzberger P, Walter DH, Rittig K, Bahlmann FH, Pola R, Curry C et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083-1092.
102. Obrosova IG. Diabetes and the peripheral nerve. Biochim Biophys Acta 2009; 1792: 931-940.